Davern Capital Partners
Davern Capital Partners reported 15 stocks worth $587M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are BNTX (12.0%), ROIV (11.7%) and RPRX (11.1%). Compared with Q1 2026, the fund opened new positions in ALNY, VERA and AVTX, added to BNTX, ROIV and RPRX, trimmed LEGN and NTRA and sold out of PFE, ARGX and LLY.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  BNTX Biontech SE | $70.2M | 12.0% | 755K | +449K (+147%) | 3 of 3 | |
| 2 |  ROIV Roivant Sciences Ltd | $68.4M | 11.7% | 1.9M | +1.1M (+121%) | 3 of 3 | |
| 3 |  RPRX Royalty Pharma PLC | $64.8M | 11.1% | 1.2M | +636K (+122%) | 3 of 3 | |
| 4 |  IONS Ionis Pharmaceuticals Inc | $63.3M | 10.8% | 799K | +412K (+106%) | 3 of 3 | |
| 5 |  INSM Insmed Inc | $59.7M | 10.2% | 560K | +377K (+207%) | 2 of 3 | |
| 6 |  REGN Regeneron Pharmaceutical | $57.8M | 9.8% | 93K | +48K (+107%) | 3 of 3 | |
| 7 |  LEGN Legend Biotech Corp | $34.4M | 5.9% | 1.2M | −123K (−9%) | 3 of 3 | |
| 8 |  ALNY Alnylam Pharmaceuticals Inc | $34M | 5.8% | 113K | New position | 1 of 3 | |
| 9 |  NTRA Natera Inc | $32.3M | 5.5% | 119K | −25K (−17%) | 3 of 3 | |
| 10 |  GPCR Structure Therapeutics Inc | $23.9M | 4.1% | 446K | +320K (+253%) | 2 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Davern Capital Partners 13F FAQ
What does Davern Capital Partners own?
Davern Capital Partners reported 15 stocks worth $587M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are BNTX (12.0%), ROIV (11.7%) and RPRX (11.1%). The table above lists every position in the filing (the top 10 without an account).
What did Davern Capital Partners buy and sell in Q2 2026?
Compared with Q1 2026: 3 new positions, 10 added to, 2 trimmed and 5 sold out. New positions include ALNY, VERA and AVTX. It sold all of PFE, ARGX and LLY.
When will Davern Capital Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Davern Capital Partners's portfolio worth?
The Q2 2026 filing reports $587M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.